TB-500 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-11-26. Numbers and descriptions here follow the published literature rather than marketing material.
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
TB-500 is a shorthand label used in supplier catalogs and online discussion for a short synthetic peptide described as a fragment of thymosin beta-4. Most product listings present it as the N-terminally acetylated heptapeptide Ac-LKKTETQ, a sequence corresponding to the actin-binding region of the parent protein. The name is not a formal chemical designation and does not appear in standard nomenclature systems. Because labeling practices vary between vendors, two products sold under the same name may not contain the same molecule, and the stated sequence should be treated as a claim rather than a fixed definition.
Thymosin beta-4 is a naturally occurring protein of 43 amino acids found in most mammalian cells, where it binds actin monomers and influences filament dynamics. It was first isolated from thymus tissue in the early 1980s, and its actin-binding activity was later mapped to a short region near the N-terminus. The synthetic fragment sold as TB-500 was designed to reproduce that region rather than the full protein. Whether a short fragment reproduces the behavior of the intact molecule remains an open question, since the parent protein carries additional structural elements outside the binding region.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H68N10O14 | Acetylated heptapeptide form |
| Monoisotopic mass | 888.5 Da | Average mass about 889 Da |
| Appearance | White to off-white solid | Usually supplied as lyophilised powder |
| Solubility class | Highly water soluble | Also dissolves in aqueous buffers |
| Common synonyms | Tbeta4 fragment, thymosin beta-4 (17-23) | Refer to the same sequence |
Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.
Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.
Interest in the fragment grew during the 1990s and 2000s, when it moved from laboratory work into sports and supplement markets. Anti-doping bodies added thymosin beta-4 fragments to prohibited lists, and a small number of adverse analytical findings have been reported in competition testing. Published controlled human trials remain scarce. Most mechanistic evidence comes from cell culture and animal models, and those studies examine endpoints such as cell migration, wound closure and inflammation markers. That evidence supports research interest but does not establish clinical benefit, and broad regenerative claims should be read as unverified.
TB-500 is a short synthetic peptide sold under a trade name rather than a systematic chemical name. Suppliers usually describe it as a fragment of thymosin beta-4 and ship it as a lyophilised powder intended for laboratory use. Because the label is commercial, the exact sequence attributed to it is not fully consistent across catalogues, and some listings present a seven-residue peptide while others describe related fragments of similar length. It is not an approved medicine in any major jurisdiction, and it is handled as a research chemical.
Interest in the peptide grew during the 2000s and 2010s, when studies of tendon and ligament injuries in horses reported changes in lesion size after treatment. Those reports circulated widely outside the scientific literature and shaped much of the current online discussion. Subsequent reviews noted inconsistent study design, small groups, and a shortage of independent replication. Popular descriptions often blur the line between the fragment, the complete protein, and unrelated growth factors, which complicates comparisons across sources.
TB-500 is a synthetic peptide whose sequence corresponds to a short fragment near the N-terminus of thymosin beta-4, a small protein present in most mammalian cells. The fragment is commonly cited as containing the actin-binding region of the parent molecule, which is why it appears in laboratory work on cell migration and tissue repair. Suppliers distribute it as a lyophilised powder intended for research use. Its identity is defined by amino acid sequence and by the presence of an acetyl group on the N-terminal residue.
The following table is based on the ISSCAAP classification (International Standard Statistical Classification of Aquatic Animals and Plants) used by the FAO to collect and compile fishery statistics. The production figures have been extracted from the FAO FishStat database, and include both capture from wild fisheries and aquaculture production.
== Methods == There is a range of IQF technologies, but the main concept is to transport the product into the freezer with the help of a processing line belt or infeed shaker. Inside the freezer, the product travels through the freezing zone and exits the other side. Product transport inside the freezer uses different technologies. Some freezers use transport belts similar to a conveyor belt. Others use bed plates that hold the product, and an asymmetrical movement makes the plate advance by itself through the freezer. There are two main IQF technologies: mechanical IQF freezers and cryogenic IQF freezers. Mechanical IQF freezers work on the principle of cold air circulation, which flows from underneath the bed plate or transport belt with the help of fans. The cold airflow passes through the pieces of product in circular motions while the product is also advancing through the freezer towards the exit. The design and efficiency of this type of IQF freezers varies among manufacturers who seek to find the perfect balance of aerodynamics for an optimal freezing result. This technology has seen impressive improvements and developments during the past 20 years, being suited for an increasing range of products. Cryogenic IQF freezers immerse the product in liquid nitrogen at very low temperatures, freezing it rapidly while continuously moving the product to avoid block or lump formation. Although this method shows good freezing results, it might lead to higher processing costs per weight of product due to the cost of the liquid nitrogen required.
=== Vitamin E === Naturally occurring vitamers of vitamin E include tocopherols (α-, β-, γ-, and δ-) and tocotrienols ( α-, β-, γ-, and δ-). Many plant-based foods provide all eight naturally occurring vitamers of vitamin E in varying amounts from different sources. Tocopherols are more abundant in commonly consumed foods relative to tocotrienols. Fortified foods and dietary supplements predominantly contain vitamin E as α-tocopherol salts, most frequently as tocopheryl acetate or vitamin E acetate. The different naturally occurring vitamers of vitamin E are not interconverted in the body and have different metabolic effects. Newly absorbed vitamers of vitamin E are transported to the liver. The liver recognizes and preferentially re-secretes α-tocopherol into circulation, making it the most abundant vitamer of vitamin E in the blood. While tocotrienols are present in lower concentrations, they have more potent antioxidant properties than α-tocopherol and can have metabolic impacts at low concentration. Normal serum concentrations of α-tocopherol in adults ranges from 5 to 20 μg/mL.
turnover number In enzymology, a measure of the rate at which a particular enzyme catalyzes a particular biochemical reaction, usually expressed as the average number of substrate molecules it is capable of converting into reaction products per unit time at a given concentration of enzyme.
=== Davis Cup === Zverev made his Davis Cup debut for Germany against the Czech Republic in 2016. He faced No. 7 Tomáš Berdych in his debut match and took a two sets to one lead before ultimately losing in five sets. After the Czech Republic won the doubles rubber while Kohlschreiber won both singles matches, Zverev faced Lukáš Rosol in a decisive fifth rubber. Rosol won the match easily to send the Czech Republic into the next round. In the 2017 against Belgium, Zverev recorded his first career match win in the competition against Arthur De Greef, but lost the doubles rubber with his brother as well as his second singles match to Steve Darcis. Belgium won the tie 4–1. Zverev won his first Davis Cup tie in 2018, winning both of his singles matches against Alex de Minaur and Kyrgios to lead Germany to a 3–1 victory over Australia. In the quarterfinals, Germany took a 2–1 lead against Spain behind Zverev's win over David Ferrer and a victory in doubles. However, Spain ultimately won the tie on the final day after Zverev was unable to defeat Nadal and Kohlschreiber lost a tight five-set match to Ferrer. In 2019, the format of the Davis Cup was changed to have eighteen countries competing in the finals over a single week in November, all but six of which were decided through a qualifying round in February. Germany was placed in the qualifying round and drawn against Hungary. Zverev participated and won both of his singles matches as Germany won the tie 5–0. He did not participate in the finals in November, in which Germany lost in the quarterfinals.
Sources: en.wikipedia.org
The Terek Cossack Host was created in 1577 by free Cossacks resettling from the Volga to the Terek River. Local Terek Cossacks joined this host later. In 1792, the host was included in the Caucasus Line Cossack Host, from which it separated again in 1860, with Vladikavkaz as its capital. In 1916, the population of the host was 255,000, within an area of 1.9 million desyatinas.
S-(2-hydroxyacyl)glutathione + H2O = glutathione + a 2-hydroxy carboxylate This enzyme belongs to the family of hydrolases, specifically the class of thioester lyases. It is commonly known as glyoxalase II. It participates in pyruvate metabolism.
The metabolism of drugs is often divided into the following three phases. Phase I: modification, phase II: conjugation, and phase III: excretion. These phases act in concert to detoxify drugs and remove them from cells and eventually from the body. The purpose of phase I is to introduce polar groups that either themselves directly facilitate excretion or to create reactive functional groups. These reactive groups can be conjugated in a phase II reaction with molecules that are recognized by transport proteins. In the last step, transport proteins eliminate the drug conjugate from the body. In phase I, enzymes such as Cytochrome P450 oxidases introduce reactive or polar groups into xenobiotics. These modified compounds are then conjugated to polar compounds in phase II reactions. These reactions are catalyzed by transferase enzymes such as glutathione S-transferases. Finally, in phase III, the conjugated xenobiotics may be further processed, before being recognized by efflux transporters and pumped out of cells. Drug metabolism often converts lipophilic compounds into hydrophilic products that are more readily excreted.
== G == GC-MS – Gas chromatography-mass spectrometry GDMS – Glow discharge mass spectrometry GDOS – Glow discharge optical spectroscopy GISAXS – Grazing incidence small angle X-ray scattering GIXD – Grazing incidence X-ray diffraction GIXR – Grazing incidence X-ray reflectivity GLC – Gas-liquid chromatography GPC – Gel permeation chromatography
Sources: en.wikipedia.org
Teratogenic effects with therapeutic doses of suvorexant in humans have not been established due to lack of research and available data. Suvorexant is pregnancy category C in the United States. It is unknown whether suvorexant is present in the breast milk, whether it affects lactation in breastfeeding women, or whether it affects breastfed infants. However, suvorexant has been found to be present in mammary milk in rats and this is likely to be the case in humans as well. Suvorexant should be used in pregnant and breastfeeding women only if the potential benefit justifies the potential for harm to the baby.
The sodium carboxymethyl cellulose can be cross-linked to give the croscarmellose sodium (E468) for use as a disintegrant in pharmaceutical formulations. Furthermore, by the covalent attachment of thiol groups to cellulose ethers such as sodium carboxymethyl cellulose, ethyl cellulose, or hydroxyethyl cellulose mucoadhesive and permeation enhancing properties can be introduced. Thiolated cellulose derivatives (see thiomers) exhibit also high binding properties for metal ions.
After Markov's death the wound on Kostov's back was examined and a ricin-laced pellet identical to the one used against Markov was removed. Several terrorist individuals and groups have experimented with ricin or planned to use it. There have been incidents of the poison being mailed to US politicians. For example, on 29 May 2013 two anonymous letters sent to New York City Mayor Michael Bloomberg contained traces of it. Another was sent to the offices of Mayors Against Illegal Guns in Washington, D.C. A letter containing ricin was also reported to have been sent to American President Barack Obama at the same time. Shannon Richardson, an actress, was later charged with the crime, and pleaded guilty that December; she was sentenced to 18 years in prison plus a restitution fine of US$367,000. On 2 October 2018, two letters suspected of containing ricin were sent to The Pentagon, one addressed to Secretary of Defense James Mattis, and the other to Chief of Naval Operations, Admiral John Richardson. A letter was received on 23 July 2019 at Pelican Bay State Prison in California which claimed to contain a suspicious substance. Authorities later confirmed it contained ricin; no detrimental exposures were identified. In 2020, some media in the Czech Republic reported, based on intelligence information, that a person carrying a Russian diplomatic passport and ricin had arrived in Prague with the intention of assassinating three politicians. Russian president Vladimir Putin denied the reports.
=== United States === In 1993, the product was approved for use in the US by the FDA, and its use began in 1994. The product is now sold in all 50 states. The FDA stated that food products made from rBST-treated cows are safe for human consumption, and no statistically significant difference exists between milk derived from rBST-treated and untreated cows. The FDA found BST to be biologically inactive when consumed by humans and found no biological distinction between rBST and BST. In 1990, an independent panel convened by the National Institute of Health supported the FDA opinion that milk and meat from cows supplemented with rBST is safe for human consumption.
The proportion of de novo genes that are protein-coding is unknown, but the appearance of "transcription first" has led some to posit that protein-coding de novo genes may first exist as RNA gene intermediates. The case of bifunctional RNAs, which are both translated and function as RNA genes, shows that such a mechanism is plausible. Neutral evolutionary modelling suggests that de novo protein-coding genes may more often emerge via a transcription-first trajectory, and that antisense overlap with existing genes can increase the probability of ORF emergence and retention. The gain of both transcription and ORF may occur simultaneously when chromosomal rearrangement is the event that precipitates gene birth.
Sources: en.wikipedia.org
No. TB-500 is a short synthetic peptide matching residues 17 to 23 of thymosin beta-4, while the parent protein contains 43 residues. The fragment lacks the rest of the protein sequence, so the two are related but not identical.
It consists of leucine, lysine, lysine, threonine, glutamic acid, threonine, and glutamine in that order. The N-terminal leucine is usually acetylated in the forms described in catalogues.
Controlled human data is limited, and most published findings come from cell culture or animal work. This makes it difficult to state clinical effects with confidence.
Most listings describe it as a short acetylated peptide with the sequence Ac-LKKTETQ, presented as a region of thymosin beta-4. The label is a trade-style name rather than a standardized chemical name, so the exact content of a given vial depends on the supplier.